دورية أكاديمية
Pharmacogenomic testing for mental health (Part I): documenting early adopter perceptions of use for eight scenarios.
| العنوان: | Pharmacogenomic testing for mental health (Part I): documenting early adopter perceptions of use for eight scenarios. |
|---|---|
| المؤلفون: | Manzor Mitrzyk B; College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA., Plegue MA; Department of Family Medicine, University of Michigan, Ann Arbor, MI 48104, USA., Kadri R; Department of Family Medicine, University of Michigan, Ann Arbor, MI 48104, USA., Danak SU; Department of Internal Medicine, Northeast Georgia Health System, Gainesville, GA 30501, USA., Hubbard JD; College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA., Kaip EA; College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA., Roberson DN; College of Medicine, University of Florida, Gainesville, FL 32610, USA., Ellingrod VL; College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA., Farris KB; College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA., Ruffin MT 4th; Department of Family & Community Medicine, Milton S. Hershey Medical Center, Penn State Health, Hershey, PA 17033, USA., Klinkman MS; Department of Family Medicine, University of Michigan, Ann Arbor, MI 48104, USA., Buis LR; Department of Family Medicine, University of Michigan, Ann Arbor, MI 48104, USA. |
| المصدر: | Personalized medicine [Per Med] 2021 May; Vol. 18 (3), pp. 223-232. Date of Electronic Publication: 2021 Mar 17. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Future Medicine Country of Publication: England NLM ID: 101238549 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-828X (Electronic) Linking ISSN: 17410541 NLM ISO Abbreviation: Per Med Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : Future Medicine, c2004- |
| مواضيع طبية MeSH: | Attitude of Health Personnel*, Attention Deficit Disorder with Hyperactivity/*drug therapy , Cytochrome P-450 Enzyme System/*genetics , Depression/*drug therapy , Pharmacogenomic Testing/*statistics & numerical data, Adult ; Attention Deficit Disorder with Hyperactivity/genetics ; Depression/genetics ; Female ; Humans ; Male ; Mental Health ; Middle Aged |
| مستخلص: | Aim: We sought to understand how early adopters used pharmacogenomic (PGx) testing for treating depression and attention deficient hyperactivity disorder (ADHD). Patients & methods: We conducted a phone survey with prescribers who had previously ordered an Informed PGx (Progenity, Inc., MI, USA) test. Results: We identified 1037 prescribers in our sampling period. Respondents (n = 64) were predominantly female (61.5%) and in pediatrics (n = 42; 64.6%). PGx testing was used for multiple scenarios (mean 3.3 ± 1.6); the most common was after no response to medication was observed (80%; 51/64). Most respondents state that test results typically reveal an altered metabolizer status. Conclusion: PGx test results ordered by early adopters often reveal altered metabolizers which leads them to change the depression/ADHD medication regimen. Future work should evaluate the clinical utility of PGx testing for depression/ADHD treatment. |
| فهرسة مساهمة: | Keywords: adverse effects; altered metabolizer status; clinical decision support; cost; early adopters; medication selection; patient confidence; quantitative; survey |
| المشرفين على المادة: | 9035-51-2 (Cytochrome P-450 Enzyme System) |
| تواريخ الأحداث: | Date Created: 20210317 Date Completed: 20211224 Latest Revision: 20211224 |
| رمز التحديث: | 20231215 |
| DOI: | 10.2217/pme-2020-0083 |
| PMID: | 33728966 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1744-828X |
|---|---|
| DOI: | 10.2217/pme-2020-0083 |